BiotechTube

Candesartan Cilexetil + Hydrochlorothiazide + Candesartan Cilexetil

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Stage II Hypertension

Conditions

Stage II Hypertension

Trial Timeline

Feb 1, 2008 → Mar 1, 2009

NCT ID
NCT00621153

About Candesartan Cilexetil + Hydrochlorothiazide + Candesartan Cilexetil

Candesartan Cilexetil + Hydrochlorothiazide + Candesartan Cilexetil is a approved stage product being developed by AstraZeneca for Stage II Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00621153. Target conditions include Stage II Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Stage II Hypertension were approved

Approved (20) Terminated (2) Active (0)
✅Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
✅Tacrolimus Extended-Release Oral CapsuleAstellas PharmaApproved
✅donepezil HCl + donepezil HClEisaiApproved
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
✅Intravenous ParicalcitolAbbVieApproved
✅Zepatier + Ribavirin + SofosbuvirMerckApproved
✅Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)NovartisApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00621153ApprovedCompleted

Competing Products

20 competing products in Stage II Hypertension

See all competitors
ProductCompanyStageHype Score
FYB206 + KeytrudaFormycon AGPhase 1
23
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
35
ALPS12 + obinutuzumabChugai PharmaceuticalPhase 1
36
LazertinibYuhanPhase 2
31
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Datopotamab deruxtecanDaiichi SankyoPhase 2
42
Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue MedicationsDaiichi SankyoPhase 1/2
39
Anastrozole + Trastuzumab DeruxtecanDaiichi SankyoPhase 2
42
Ifinatamab deruxtecan + Atezolizumab + CarboplatinDaiichi SankyoPhase 1/2
39
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
36
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Fezolinetant + PlaceboAstellas PharmaPhase 2
42
Conversion to Advagraf + conversion of non-immunosuppressant drugs to once daily + Conversion to once daily MPAAstellas PharmaPre-clinical
30
Astagraf XL + Prograf + Mycophenolate mofetilAstellas PharmaApproved
43
Tacrolimus Extended-Release Oral CapsuleAstellas PharmaApproved
43
Roxadustat + Epoetin AlfaAstellas PharmaPhase 2
35
Denileukin diftitoxEisaiPhase 2
35
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
32